Julie Méthot
Laval University
40 Papers
241 Citations
Julie Méthot is an academic researcher from Laval University. The author has contributed to research in topics: Alipogene tiparvovec & Lipoprotein lipase deficiency. The author has an hindex of 13, co-authored 38 publications. Previous affiliations of Julie Méthot include Université de Montréal.
Chat about Author
Papers
Gene therapy for lipoprotein lipase deficiency.
TL;DR: The overall benefit–risk ratio of AAV1-LPLS447X gene therapy appears positive to date, particularly for the patients presenting the highest risk of complications.
173
Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Bettina A. Hamelin,Asmàa Bouayad,Julie Méthot,Jean Jobin,Pierre Desgagnés,Paul Poirier,Joakim Allaire,Jean Gaston Dumesnil,Jacques Turgeon +8 more
TL;DR: It is concluded that diphenhydramine inhibits the metabolism of metoprolol in extensive metabolizers, thereby prolonging the negative chronotropic and inotropic effects of the drug.
141
Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency
Daniel Gaudet,Janneke de Wal,Karine Tremblay,S. Déry,Sander van Deventer,Andreas P. Freidig,Diane Brisson,Julie Méthot +7 more
TL;DR: Alipogene tiparvovec (AAV1-LPL(S447X) gene therapy is developed to prevent complications and decrease the clinical morbidity of lipoprotein lipase deficiency (LPLD).
135
Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis
Daniel Gaudet,Erik S.G. Stroes,Julie Méthot,Diane Brisson,Karine Tremblay,Sophie J. Bernelot Moens,Giorgio Iotti,Irene Rastelletti,Diego Ardigò,Deyanira Corzo,Christian Meyer,M. Andersen,Philippe Ruszniewski,Mark Deakin,Marco J. Bruno +14 more
TL;DR: Results from this long-term analysis suggest that alipogene tiparvovec was associated with a lower frequency and severity of pancreatitis events, and a consequent overall reduction in health care resource use up to 6 years posttreatment.
92
Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics.
TL;DR: Results indicate that genetic factors known to contribute to the etiology and clinical expression of hypertriglyceridemia subtypes also modulate the response to triglyceride-lowering drugs.
25